These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis. Lv Z, Song L, Wang M, Hou H, Li H, Wang X, Wang J, Wang J, Liu M. Chin Med J (Engl); 2024 Apr 20; 137(8):949-958. PubMed ID: 37690993 [Abstract] [Full Text] [Related]
7. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M. Ann Nucl Med; 2019 Dec 20; 33(12):891-898. PubMed ID: 31502084 [Abstract] [Full Text] [Related]
11. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. Zhao G, Ji B. AJR Am J Roentgenol; 2022 Sep 20; 219(3):386-395. PubMed ID: 35441529 [Abstract] [Full Text] [Related]
13. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ. J Nucl Med; 2017 Feb 20; 58(2):235-242. PubMed ID: 27635024 [Abstract] [Full Text] [Related]
14. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L. J Nucl Med; 2021 Aug 01; 62(8):1075-1081. PubMed ID: 33277398 [Abstract] [Full Text] [Related]
15. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Lin CY, Lee MT, Lin CL, Kao CH. Clin Nucl Med; 2019 May 01; 44(5):365-376. PubMed ID: 30888999 [Abstract] [Full Text] [Related]
16. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Eur Urol; 2020 Apr 01; 77(4):403-417. PubMed ID: 30773328 [Abstract] [Full Text] [Related]
19. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F. Urol Oncol; 2022 Jan 01; 40(1):6.e1-6.e9. PubMed ID: 34400066 [Abstract] [Full Text] [Related]
20. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C. J Nucl Med; 2018 Sep 01; 59(9):1373-1379. PubMed ID: 29371410 [Abstract] [Full Text] [Related] Page: [Next] [New Search]